Tunneling nanotube–mediated intercellular filamin A transport mechanosensitively programs osteoclastogenesis in myeloma bone disease

View at publisher
Authors: Jing Ru Guo, Jingjing Wang, Ying Xie, Yixuan Wang, Ziyi Peng, Mengdi Wang, Hao Cheng, Tiantian Li, Linchuang Jia, Hongwei Xu, Danchen Su, Mu Qiao
+9 more Huan Liu, Keqing Li, Wenjing Li, Di Wu, Jianyong Huang, Peter Leif Bergsagel, F. Li, Zhigang Zhao, Zhiqiang Liu
Cited by: 1
References: 30

Abstract

ABSTRACT: Intercellular communication between multiple myeloma (MM) cells and osteoclast precursor cells (pre-OCs) contributes extensively to the occurrence and development of myeloma-related bone destruction. However, key interacting modes and the exchanged substances involved in this communication remain unclear. In this study, we discover that tunneling nanotubes (TNTs) directly connect MM and pre-OCs. Using the stable isotope labeling with amino acids in cell culture assay and a positive-negative double selection strategy, we identify filamin A (FLNA) as a major protein transported from MM to pre-OCs. FLNA acts as a molecular clutch linking extracellular matrix-bound MAC1 to the cytoskeleton, activating Rho and MAPK signaling pathways and promoting F-actin polymerization, which subsequently enhances osteoclast differentiation by modulating cellular stiffness, traction force, and deformability. In addition, FLNA directly binds vinculin and promotes its recruitment to podosomes, thereby enhancing the functions of podosomes and the bone resorption capacity of osteoclasts. The conditional depletion of Flna in mice suppresses podosome activity and reduces stiffness, traction force, and deformability in pre-OCs, leading to significantly impaired osteoclast differentiation and increased bone mass. In the Vk∗MYC mouse model of myeloma, the administration of the TNT inhibitor latrunculin B disrupts FLNA transport to osteoclasts and alleviates osteolytic bone disease. These findings highlight the critical role of MM-transferred FLNA in osteoclastogenesis and suggest that targeting TNTs may represent a therapeutic strategy to limit pathological bone resorption associated with MM.

Fields of Study & Subjects

Bone Metabolism and Diseases Multiple Myeloma Research and Treatments Bone health and treatments

Publication details

Journal / source
Blood
Publisher
American Society of Hematology
Volume
148
Issue
5
Pages
581–597
Publication date
8 April 2026
Language
EN